78 results on '"Idelalisib -- Research"'
Search Results
2. New Findings on Lymphoma from Panjab University Summarized (Derivative Spectrophotometric Methods for Determination of Idelalisib In Bulk and In Formulation)
3. Department of Internal Medicine Researchers Provide Details of New Studies and Findings in the Area of Chronic Lymphocytic Leukemia (Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK ...)
4. Research Data from Second Xiangya Hospital Update Understanding of Obesity, Fitness and Wellness (Pi3k3 Mediates Fibrosis By Patient-derived Vitreous)
5. New Findings Reported from Technical University Dresden (TU Dresden) Describe Advances in Immunologic Receptors (b1 integrin mediates unresponsiveness to PI3Ka inhibition for radiochemosensitization of 3D HNSCC models)
6. Findings from Mazandaran University of Medical Sciences in the Area of Acute Myeloid Leukemia Reported (Glucose Metabolism In Acute Myeloid Leukemia Cell Line Is Regulated Via Combinational Pi3k/akt/mtor Pathway Inhibitors)
7. Research from University of Iowa Broadens Understanding of Leukemia (PI3Kd Inhibition Potentiates Glucocorticoids in B-lymphoblastic Leukemia by Decreasing Receptor Phosphorylation and Enhancing Gene Regulation)
8. Reports Summarize Lymphoma Findings from Panjab University (Validated Spectrofluorimetric Method for Estimation of Idelalisib In Bulk and In Formulation)
9. Bu Ali Sina University Details Findings in Seizures (Idelalisib, a Selective Phosphatidylinositol-3-kinase Inhibitor, Suppresses Pentylenetetrazole-induced Convulsions In Wistar Rats)
10. Studies in the Area of Biology Reported from University of Cologne (Functional Impact and Molecular Binding Modes of Drugs That Target the Pi3k Isoform P110 Delta)
11. Research Results from University of Cologne Update Knowledge of Biology (Functional impact and molecular binding modes of drugs that target the PI3K isoform p110d)
12. Cochin Hospital Researchers Release New Study Findings on Enzymes and Coenzymes (Management of Gastro-Intestinal Toxicity of the Pi3 Kinase Inhibitor: Optimizing Future Dosing Strategies)
13. Researchers at University of Maryland Eastern Shore Release New Study Findings on Prostate Cancer (Molecular Insight into Drug Resistance Mechanism Conferred by Aberrant * * PIK3CD* * Splice Variant in African American Prostate Cancer)
14. Research from Rostock University Medical Center Has Provided New Data on Apoptosis (Combined BCL-2 and PI3K/AKT Pathway Inhibition in * * KMT2A* * -Rearranged Acute B-Lymphoblastic Leukemia Cells)
15. New Mantle Cell Lymphoma Study Results Reported from Karolinska University [A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells]
16. City of Hope National Medical Center Details Findings in Chronic Lymphocytic Leukemia (Current Status of Phosphoinotiside-3 Kinase Inhibitors In Blood Cancers)
17. Studies from Northwestern University Feinberg School of Medicine Add New Findings in the Area of Cancer (Financial Toxicity and Quality of Life in Patients Taking Oral Therapy for Hematologic Malignancies)
18. Findings from Weill Cornell Medicine Advance Knowledge in Mantle Cell Lymphoma (Rates of Ibrutinib Uptake Among Black Patients with Lymphoma in SEER-Medicare Increased over Time)
19. Erciyes University Researchers Publish New Study Findings on Neuropathy (Ibrutinib Related Neuropathy: A Case Report)
20. Findings on Pharmacology Reported by Investigators at University of South China [Development of Pi3k Inhibitors: Advances In Clinical Trials and New Strategies (Review)]
21. New Acute Myeloid Leukemia Study Findings Have Been Reported from University Health Network (Enhancing Therapeutic Efficacy of Double Negative T Cells against Acute Myeloid Leukemia Using Idelalisib)
22. Findings from Fudan University Yields New Data on Acute Myeloid Leukemia (Bioisosteric Replacements of the Indole Moiety for the Development of a Potent and Selective Pi3k Delta Inhibitor: Design, Synthesis and Biological Evaluation)
23. Humboldt University Berlin Researchers Provide New Insights into Pharmaceutical Research (Impact of Selected Small-Molecule Kinase Inhibitors on Lipid Membranes)
24. Findings from Harvard Medical School Yields New Findings on Chronic Lymphocytic Leukemia (Activation of the Mapk Pathway Mediates Resistance To Pi3k Inhibitors In Chronic Lymphocytic Leukemia)
25. Researchers at Peking University Publish New Study Findings on Cell Therapy (Targeting T-cell malignancies using allogeneic double-negative CD4-CAR-T cells)
26. New Anticancer Agents Study Results Reported from Southwest Medical University (Pi3k/akt/mtor Signaling As Targets for Developing Anticancer Agents From Marine Organisms)
27. New Findings from University of Santiago Describe Advances in Vascular Diseases and Conditions (The Pi3k Delta Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential)
28. Reports from University of Milan Describe Recent Advances in Anticancer Agents (Ab Initio Spectroscopic Investigation of Pharmacologically Relevant Chiral Molecules: The Cases of Avibactam, Cephems, and Idelalisib as Benchmarks for Antibiotics ...)
29. Research from Center for Research Provides New Data on Vascular Diseases and Conditions (The PI3Kd Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential)
30. New Kinase Inhibitors Data Have Been Reported by Researchers at Ludwig-Maximilians-University Munich (The PI3K -Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression)
31. Findings from University of Ljubljana Has Provided New Information about Chronic Lymphocytic Leukemia (EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia ...)
32. Study Data from Jean-Marie Michot et al Provide New Insights into B-Cell Lymphoma (Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?)
33. Studies from University of Picardie Jules Verne Reveal New Findings on Chronic Lymphocytic Leukemia [Ascorbic acid (vitamin C) synergistically enhances the therapeutic effect of targeted therapy in chronic lymphocytic leukemia]
34. Studies Conducted at Jubilant Biosystems Ltd. on PI3K Inhibitors Recently Reported (Validated HPLC-UV method for simultaneous quantification of PI3K inhibitors, copanlisib, duvelisib and idelalisib in rat plasma: Application to a ...)
35. Research Reports on Lymphoma from CEITEC Masaryk University Provide New Insights (Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies)
36. New Kinase Inhibitors Study Findings Have Been Reported by Researchers at Jiangnan University (Computational Investigation of the Selectivity Mechanisms of Pi3k Delta Inhibition With Marketed Idelalisib: Combined Molecular Dynamics Simulation ...)
37. Findings on Follicular Lymphoma Described by Researchers at Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS) (PI3Kd inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of ...)
38. Research from Rostock University Medical Center in Cancer Research Provides New Insights (Combination of the PI3K inhibitor Idelalisib with the conventional cytostatics cytarabine and dexamethasone leads to changes in pathway activation that ...)
39. New Findings from Michigan State University Describe Advances in Chemical Modeling (Generative Network Complex for the Automated Generation of Drug-like Molecules)
40. New Antineoplastics Findings Reported from Memorial Sloan-Kettering Cancer Center (Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation In Cll Reveals Btk Inhibition As an Effective Strategy)
41. Findings from University of Southern Florida Broaden Understanding of Kinase Inhibitors (The Dual Pi3k Delta/ck1 Epsilon Inhibitor Umbralisib Exhibits Unique Immunomodulatory Effects On Cll T Cells)
42. Reports on Chronic Lymphocytic Leukemia from Oregon Health & Science University (OHSU) Provide New Insights (Phase Ib Study of Tirabrutinib In Combination With Idelalisib or Entospletinib In Previously Treated Chronic Lymphocytic Leukemia)
43. Findings from Johns Hopkins University School of Medicine Broaden Understanding of Colitis (A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal ...)
44. Recent Findings in Chronic Lymphocytic Leukemia Described by Researchers from Laval University (Ugt2b17 Modifies Drug Response In Chronic Lymphocytic Leukaemia)
45. Researcher from Titu Maiorescu University Publishes New Studies and Findings in the Area of Chronic Lymphocytic Leukemia (Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy ...)
46. Studies from Ohio State University Yield New Information about Chronic Lymphocytic Leukemia (Resistance Mechanisms To Targeted Agents In Chronic Lymphocytic Leukemia)
47. Recent Research from Harvard University School of Medicine Highlight Findings in Cancer Research (Phosphatidylinositol 3 Kinase Delta Inhibitors Present and Future)
48. Reports Summarize Chronic Lymphocytic Leukemia Findings from School of Biochemistry and Immunology (Selected Nitrostyrene Compounds Demonstrate Potent Activity In Chronic Lymphocytic Leukaemia Cells, Including Those With Poor Prognostic Markers)
49. Findings on Chronic Lymphocytic Leukemia Detailed by Investigators at Zucker School of Medicine at Hofstra Northwell (How Have Targeted Agents Changed the Treatment Landscape for Elderly Patients With Cll?)
50. Data on Acute Myeloid Leukemia Reported by Researchers at University of Science and Technology China (Bcl-2 Inhibitor Synergizes With Pi3k Delta Inhibitor and Overcomes Flt3 Inhibitor Resistance In Acute Myeloid Leukaemia)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.